Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin in Squamous Cervical Intraepithelial Neoplasias (CIN3)
NCT02554344Phase 1Withdrawn
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of curcumin in cervical intraepithelial neoplasia (CIN), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Safety and Feasibility Assessed by CTCAE v4.0 at 4 months. Planned start Jun 2015; status: withdrawn.
02
Drugs
curcumin
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02554344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02554344.